East Sunshine is about to take the first copy of Liglitin
-
Last Update: 2020-07-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Pharmaceutical Network July 8th, recently, The East Sunshine Drug's Ligretin tablets (acceptance number CYHS1800162) imitation 4 categories of listing applications into the administrative approval stage, the first imitation is about to be taken downAccording to Minnet.com, sales of Ligretin tablets at the end of China's public medical institutions in 2019 were 246 million yuanIt is worth mentioning that since the domestic listing of Ligretin tablets in the domestic market sales, the annual growth rate of more than 100%Liglitin is a dipeptide-4 (DPP-4) inhibitor that improves blood glucose control in patients with type 2 diabetesThe Liglitin tablets were developed by Bollinger Ingham Pharmaceuticals and were approved for import by the State Drug Administration in 2013According to The Inner Net, sales of Ligretin tablets at the
end sepsis of publichospitals in China in 2019 were 246 million yuan, as were publichospitals in China, county-level public hospitals, urban community centers and township hospitals (china's public medical institutions)It is worth mentioning that since the domestic listing of Ligretin tablets in the domestic market sales, the annual growth rate of more than 100%China's public medical institutions terminal Ligretin tablet sales (units: 10,000 yuan)THE rapid oral absorption of DPP-4 inhibitors, the current domestic has been approved for listing of DPP-4 inhibitors have 5, respectively, Siglitin, Sagretin, Viglitin, Liglitin and AglitinLiglitin is currently the lowest level of renal excretion of DPP-4 inhibitors, is the first approved DPP-4 inhibitor without reducing doses based on renal functionOf the five DPP-4 inhibitors, Sigretin, Sagretin, Vigretin and Agretin have all been approved for saleEast Sunshine's listapplication for ligretin tablets entered the CDE Review Center in July 2018, was given priority review in September 2018 on the grounds that "the same production line is produced and is listed in the United States or the European Union", and the status changed to "in approval" on July 1, 2020, will be taken to the lead copy of the Liglitin tabletSource: Minnet Database
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.